A Registry Study on Biomarkers of Pulmonary Embolism
A Registry Study on Biomarkers of Pulmonary Embolism
The purpose of the study is to evaluate the value of biomarkers in the diagnosis and risk
 stratification of patients with suspected pulmonary embolism.
Management of patients with acute pulmonary embolism is a serious problem. The rapid and
 accurate diagnosis and risk stratification of these patients is an important unmet clinical
 need. The aim of the study is to evaluate the value of biomarkers, alone or in combination,
 in the diagnosis and risk stratification of patients with suspected pulmonary embolism
 presenting to the emergency department.
Inclusion Criteria:

 -  Patient aged ≥ 18 years that presents to an emergency department

 -  With suspected PE defined as new onset of or worsening of shortness of breath or chest
 pain

 Exclusion Criteria:

 -  Hemodynamic instability

 -  Life expectancy less than 3 months

 -  First symptoms 15 day or more before inclusion

 -  Inability to the follow-up visits

 -  Therapeutic anticoagulation for any indication